Vivoryon Therapeutics N.V.
VVY.ASHealthcareLEI 3912004AMB0KGZXZYJ15
At a glance
- Most recent filing on April 22, 2026 — a trade by Irsfeld M. on Apr 17, 2026.
- Over the past 90 days: 0 open-market buys.
- This page shows 7 visible filings, of which 1 open-market buys, going back to August 9, 2023.
This buy came out above 77% of all scored insider buys of the past twelve months. A rank, not a forecast.
How the company itself measures up
Four components from the annual figures and the price series, compared with the other companies on the same date. Separate from the filing above, and separate from the question of whether this is a good moment.
On this measurement the company came out above 26% of the companies measured. That says something about the company's numbers, not about its share price.
As of Jul 31, 2026 · methodology 0.4.0
| Component | What is measured | Sub-score | Weight | Compared with |
|---|---|---|---|---|
| Quality | gross profit relative to total assets | — | not measured — reweighted | |
| Valuation | operating profit relative to the value of the whole business | 58% | all measured companies | |
| Momentum | price return over twelve months, excluding the most recent month | 42% | all measured companies | |
| What goes to shareholders | dividends and share buybacks relative to market value | — | not measured — reweighted |
Labels on this measurement: Little could be measured · Market value below our floor. These are notes about the data. Nothing is subtracted from the score, and it is not a warning about the company.
These figures only mean something in comparison: they take on meaning next to the other companies of that same date. See the full ranking →
Price history and buy moments
- 1 marked buy:
- Nov 2, 2023 · price 7.96
Every visible filing
What was filed, most recent first. On an award the register reports a price of 0 — nothing was paid — and then the Quantity column tells you how large the filing was.
| Reported | Filed by | Role | Category | Quantity | Amount |
|---|---|---|---|---|---|
| Apr 22, 2026 | Irsfeld M. | CFO | Award | 60,000 | nothing paid |
| Oct 21, 2025 | Irsfeld M. | CFO (not formally appointed as director within the meaning of Dutch Corporate law) | Award | 20,000 | nothing paid |
| Nov 7, 2023 | Gocalves Cacela Matias S. | CEO | Open-market buy | 10,600 | €83,740 |
| Aug 9, 2023 | Weber F. | Chief Medical Officer | Award | 180,000 | nothing paid |
| Aug 9, 2023 | Weber F. | Chief Medical Officer | Award | 90,000 | nothing paid |
| Aug 9, 2023 | Weber F. | Chief Medical Officer | Award | 60,000 | nothing paid |
| Aug 9, 2023 | Doering A. | Head of Investor Relations | Award | 100,000 | nothing paid |
Follow this company
Loading follow status…
The insider, quant and timing scores stand apart from one another and are meant as context. There is no threshold in them (“above such and such is worth buying”), we do not add them up into a single figure, and none of it is a recommendation. How they are calculated is in the methodology.